company background image

Guardant Health NasdaqGS:GH Stock Report

Last Price


Market Cap







30 Sep, 2022


Company Financials +
GH fundamental analysis
Snowflake Score
Future Growth2/6
Past Performance0/6
Financial Health3/6

GH Stock Overview

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally.

Guardant Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Guardant Health
Historical stock prices
Current Share PriceUS$53.83
52 Week HighUS$121.26
52 Week LowUS$27.65
1 Month Change7.53%
3 Month Change23.29%
1 Year Change-49.93%
3 Year Change-16.76%
5 Year Changen/a
Change since IPO67.17%

Recent News & Updates

Aug 15
Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

GHUS HealthcareUS Market

Return vs Industry: GH underperformed the US Healthcare industry which returned 9.1% over the past year.

Return vs Market: GH underperformed the US Market which returned -21.5% over the past year.

Price Volatility

Is GH's price volatile compared to industry and market?
GH volatility
GH Average Weekly Movement10.3%
Healthcare Industry Average Movement8.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.8%

Stable Share Price: GH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: GH's weekly volatility (10%) has been stable over the past year.

About the Company

20111,373Helmy Eltoukhy

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials.

Guardant Health, Inc. Fundamentals Summary

How do Guardant Health's earnings and revenue compare to its market cap?
GH fundamental statistics
Market CapUS$5.50b
Earnings (TTM)-US$551.10m
Revenue (TTM)US$408.13m


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GH income statement (TTM)
Cost of RevenueUS$132.95m
Gross ProfitUS$275.18m
Other ExpensesUS$826.28m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-5.39
Gross Margin67.43%
Net Profit Margin-135.03%
Debt/Equity Ratio356.0%

How did GH perform over the long term?

See historical performance and comparison